Combined AMIGOs: Adverse Events

Nausea

• Mostly mild/moderate in intensity

• Low incidence of severe nausea (placebo 1%, exenatide 4%)

• Dropouts due to nausea low (placebo ə%, exenatide 3%)

• More frequent early and incidence decreased over time

Hypoglycemia

• Mostly mild/moderate in intensity

• No difference observed from placebo in metformin study

• Incidence higher in SFU-treated patients

Previous slide

Next slide

Back to first slide

View graphic version